Chemistry & Sequence Reference
Identity fields below are based on public chemistry or biomedical reference records where available. Batch-specific purity, identity, counter-ion and analytical results should be verified against the documentation for the selected stock source.
Overview
This OMNIX catalog item is a 10 mg research blend containing 5 mg cagrilintide and 5 mg semaglutide. Cagrilintide is a long-acting amylin analogue, while semaglutide is a GLP-1 receptor agonist; each component has a separate public chemistry record.
For a blend, CAS numbers, molecular formulas and PubChem identifiers should be retained at the component level rather than collapsed into a single artificial molecular identity.
This product is strictly for research purposes only. Not approved for human or animal use.
Reference: Cagrilintide – NIH PubChem | Semaglutide – NIH PubChem
Key Characteristics
MOLECULAR PROFILE
Formula: Two-component blend: C194H312N54O59S2 + C187H291N45O59
Weight: Two-component blend — no single molecular weight
CAS: 1415456-99-3 + 910463-68-2
Sequence / Composition: Cagrilintide 5mg + Semaglutide 5mg per 10mg vial (per OMNIX PDF)
PHYSICAL PROPERTIES
Form: Lyophilized two-component peptide blend
Solubility: Blend behavior depends on formulation and excipients; verify against batch documentation.
Stability: Two-component research blend; analytical identity should be verified for both components.
Storage: Store lyophilized material frozen for long-term research storage; follow the batch-specific COA.







